High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer

55 Background: Prostate cancer accounts for greater than 200,000 cases each year. Although cancer control is generally favorable with treatment, side effects are common. Among men treated with surgery, nerve-sparing prostatectomy is associated with lower rates of incontinence and erectile dysfunction. Seminal vesicle sparing (SVS) may further limit damage to the neurovascular tissue surrounding the prostate. Although some surgeons practice SVS, evidence supporting its use is lacking. We implemented a randomized control trial to determine if SVS is associated with better functional outcomes compared to non-SVS prostatectomy. Methods: 140 men with early-stage (T1c/T2N0M0, Gleason score <= 7) prostate cancer and adequate erectile function (IIEF >= 21) were enrolled in the Seminal Vesicle Sparing Prostatectomy Trial (NCT01825642) and randomized to either SVS or non-SVS prostatectomy between 2006 and 2011. The Expanded Prostate Cancer Index Composite (EPIC) was used to assess quality of life outcomes following surgery. Results: 71 and 69 men were enrolled in the SVS and non-SVS arms, respectively. The predominant surgical approach was robotic assisted prostatectomy (>97% in both arms). Men in the SVS arm were slightly younger (56 vs 58 years, p = 0.02); however, there were no significant differences in other clinical or demographic factors. There were no cases of seminal vesicle invasion. PSA recurrence was noted in 3 patients (1 in SVS group and 2 in non-SVS group). At 12 months postoperatively, sexual (76 vs 75) and urinary incontinence (92 vs 94) scores were similar among SVS and non-SVS patients (both p > 0.2). Conclusions: Recovery of urinary and sexual function was common among men undergoing SVS or non-SVS prostatectomy. SVS did not negatively impact cancer control, but was not associated with enhanced recovery of sexual or urinary function, perhaps due to the high level of recovery of the control arm. Clinical trial information: NCT01825642. [Table: see text]

Download Full-text

1188: Time to PSA Recurrence after Radical Prostatectomy and Risk of Prostate Cancer Specific Mortality

The Journal of Urology ◽

10.1016/s0022-5347(18)33413-x ◽

2006 ◽

Vol 175 (4S) ◽

pp. 382-382

Author(s):

Stephen J. Freedland ◽

Elizabeth B. Humphreys ◽

Leslie A. Mangold ◽

Mario Eisenberger ◽

Alan W. Partin

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Specific Mortality ◽

Psa Recurrence ◽

Cancer Specific Mortality

Download Full-text

805: High-Level Cyclin D1 is Associated with High Gleason Grade and Predicts Worse Biochemical-Free Survival in Prostate Cancer

The Journal of Urology ◽

10.1016/s0022-5347(18)33041-6 ◽

2006 ◽

Vol 175 (4S) ◽

pp. 260-260

Author(s):

Rile Li ◽

Hong Dai ◽

Thomas M. Wheeler ◽

Anna Frolov ◽

Gustavo Ayala

Keyword(s):

Prostate Cancer ◽

Cyclin D1 ◽

Gleason Grade ◽

Free Survival ◽

High Level

Download Full-text

479: Prostate-Specific Membrane Antigen (PSMA) Expression as a Predictor of Prostate Cancer Progression

The Journal of Urology ◽

10.1016/s0022-5347(18)32735-6 ◽

2006 ◽

Vol 175 (4S) ◽

pp. 155-156

Author(s):

Matthias D. Hofer ◽

Sven Perner ◽

Haojie Li ◽

Rainer Kuefer ◽

Richard E. Hautmann ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Progression ◽

Prostate Specific Membrane Antigen ◽

Prostate Cancer Progression ◽

Specific Membrane ◽

Psma Expression

Download Full-text

Heterogenous PSMA expression in primary tumor of prostate cancer as a reason for negative 68 Ga-PSMA PET/CT scan? Immunohistochemical validation of 40 patients undergoing radical prostatectomy

10.1055/s-0040-1708334 ◽

2020 ◽

Author(s):

W Cytawa ◽

S Kircher ◽

C Lapa ◽

AK Buck ◽

B Brockhuis ◽

...

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Ct Scan ◽

Primary Tumor ◽

Psma Pet ◽

Pet Ct ◽

Pet Ct Scan ◽

Psma Expression

Download Full-text

Id proteins expression in prostate cancer: high-level expression of Id-4 in primary prostate cancer is associated with development of metastases

Modern Pathology ◽

10.1038/modpathol.3800602 ◽

2006 ◽

Vol 19 (7) ◽

pp. 931-941 ◽

Cited By ~ 38

Author(s):

Hiu-Fung Yuen ◽

Chee-Wai Chua ◽

Yuen-Piu Chan ◽

Yong-Chuan Wong ◽

Xianghong Wang ◽

...

Keyword(s):

Prostate Cancer ◽

High Level Expression ◽

Id Proteins ◽

Primary Prostate Cancer ◽

High Level

Download Full-text

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy

Cancers ◽

10.3390/cancers13122938 ◽

2021 ◽

Vol 13 (12) ◽

pp. 2938

Author(s):

Liam Widjaja ◽

Rudolf A. Werner ◽

Tobias L. Ross ◽

Frank M. Bengel ◽

Thorsten Derlin

Keyword(s):

Prostate Cancer ◽

Whole Body ◽

Biochemical Response ◽

Clinical Parameters ◽

Castration Resistant Prostate Cancer ◽

Radioligand Therapy ◽

Castration Resistant ◽

Psa Response ◽

High Age ◽

Psma Expression

177Lu-Prostate-specific membrane antigen (PSMA)-radioligand therapy (RLT) is a promising treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC). We aimed to determine the predictive value of pretherapeutic PSMA-ligand positron emission tomography (PET) and established clinical parameters for early biochemical response after two cycles of RLT. In total, 71 mCRPC patients who had undergone PET/computed tomography (CT) with 68Ga-PSMA-11 prior to two cycles of 177Lu-PSMA-617 RLT were included. Malignant lesions on pretherapeutic PET/CTs were manually segmented and average maximum PSMA expression (maximum standardized uptake values, SUVmax), whole-body PSMA-tumor volume (TV), and whole-body total lesion (TL)-PSMA were calculated. We then tested the predictive performance of these parameters for early biochemical response (defined as prostate-sepcific antigen (PSA) decrease of ≥50% according to PCWG2) after two cycles of RLT, relative to established clinical parameters. Early PSA response was observed in 34/71 patients. PSA change after two cycles of RLT correlated with pretherapeutic SUVmax (r = −0.49; p < 0.001), but not with PSMA-TV (r = 0.02; p = 0.89) or TL-PSMA (r = −0.15; p = 0.22). A cut-off of 19.8 for SUVmax and 75.5 years for age was defined by receiver operating characteristics and revealed a significant outcome difference for early biochemical response between patients with adversely low vs. high PSMA expression and low vs. high age (p < 0.001). Multivariate analysis identified SUVmax (HR, 7.94, p = 0.001) and age (HR, 8.05, p = 0.002) as independent predictors for PSA response early in the treatment course. Thus, high age and high PSMA expression in patients scheduled for RLT identify patients with early biochemical response. This study provides a rationale for further prospective studies exploring PET-guided treatment intensification in selected patients.

Download Full-text

SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence

The Prostate ◽

10.1002/pros.24218 ◽

2021 ◽

Author(s):

Silvia Hernández‐Llodrà ◽

Laura Segalés ◽

Nuria Juanpere ◽

Tech Marta Lorenzo ◽

Marta Salido ◽

...

Keyword(s):

Prostate Cancer ◽

Tumor Grade ◽

Pten Loss ◽

Psa Recurrence

Download Full-text

Recent trends in carbon nanotubes based prostate cancer therapy: A biomedical hybrid for diagnosis and treatment

Current Drug Delivery ◽

10.2174/1567201818666210224101456 ◽

2021 ◽

Vol 18 ◽

Author(s):

Raja Murugesan ◽

Sureshkumar Raman

Keyword(s):

Prostate Cancer ◽

Carbon Nanotubes ◽

Drug Delivery ◽

Drug Loading ◽

High Surface ◽

High Surface Area ◽

High Capacity ◽

Chemical Properties ◽

Diagnosis And Treatment ◽

High Level

: At present treatment methods for cancer are limited, partially due to the solubility, poor cellular distribution of drug molecules and, the incapability of drugs to annoy the cellular barriers. Carbon nanotubes (CNTs) generally have excellent physio-chemical properties, which include high-level penetration into the cell membrane, high surface area and high capacity of drug loading by in circulating modification with bio-molecules, project them as an appropriate candidate to diagnose and deliver drugs to prostate cancer (PCa). Additionally, the chemically modified CNTs which have excellent 'Biosensing' properties therefore makes it easy for detecting PCa without fluorescent agent and thus targets the particular site of PCa and also, Drug delivery can accomplish a high efficacy, enhanced permeability with less toxic effects. While CNTs have been mainly engaged in cancer treatment, a few studies are focussed on the diagnosis and treatment of PCa. Here, we detailly reviewed the current progress of the CNTs based diagnosis and targeted drug delivery system for managing and curing PCa.

Download Full-text

Association of genes copy number in extracellular DNA in patients with prostate cancer and sensitivity to radiotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e15014 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e15014-e15014

Author(s):

Denis S. Kutilin ◽

Mikhail S. Zinkovich ◽

Marina A. Gusareva ◽

Aleksandr V. Faenson ◽

Elena A. Karnauhova ◽

...

Keyword(s):

Prostate Cancer ◽

Blood Plasma ◽

Copy Number ◽

Extracellular Dna ◽

Biochemical Relapse ◽

Prostate Tumors ◽

Molecular Features ◽

Number Variation ◽

Invasive Method ◽

High Level

e15014 Background: Radiotherapy (RT) is one of the main treatments for prostate cancer (PC). The effectiveness of such therapy depends on the initial radioresistance of tumor cells, which is ensured by their certain molecular features, which include the genes copy number variation (CNV). Model experiments on cell cultures (obtained from surgical material) have shown that CNVs have high potential as predictors of RT sensitivity. However, this potential is limited by the high level of invasiveness in obtaining biomaterials. A possible solution to this problem lies in the transition to CNV study in the extracellular DNA (cfDNA) of blood plasma. The aim of the study was to screen predictors of radioresistant PC based on the genes CNV in cfDNA. Methods: The study included 400 patients with diagnosed PC (T2a-3bN0M0, st. II-III), 40 of them after RT had a state of biochemical relapse (RT was performed on a Novalis TX linear accelerator (Varian, USA) (TFDisoeff = 75 Gr), mean time to biochemical relapse 7.5 months). Blood samples were separated into plasma and cell fraction by centrifugation. Isolation of cfDNA from blood plasma was performed using a set of reagents “DNA-Plasma-M” (Russia). Determination of the relative CNV of 13 genes (CDK1, CCND3, CDKN1B, TP53, PTEN, BCL2, XRCC4, BAX, RBBP8, H2AX, BRCA2, RAD50, EP300) was performed using the Real-Time qPCR method. Differences were assessed using the Mann-Whitney test; the Benjamin-Hochberg correction was used to correct multiple comparisons. Results: In the group with biochemical relapse (n = 40), the CNV of genes CDK1, CDKN1B, RBBP8, XRCC4, BRCA2 and RAD50 was statistically significantly (p < 0.05) higher by 2.0 times, 2.3 times, 2.1 times, 1.4 times, 2.4 times and 2.8 times, respectively, relative to the CNV of these genes in the cfDNA of the group without relapse (n = 360). Conclusions: Thus, it was found that the CNV of 6 genes (CDK1, CDKN1B, RBBP8, XRCC4, BRCA2 and RAD50) may be a potential molecular marker of radiosensitivity of prostate tumors. Based on the obtained data, a low invasive method for determining the prostate tumors sensitivity to RT has been developed.

Download Full-text